|Back to main|
One US IPO planned for the week of Dec 17
By: Renaissance Capital
IPOs are expected to price this week
Audeo Oncology ( AURX ), which is developing a combination therapy in Phase 3 trial for metastatic colorectal cancer, plans to raise $49 million by offering 3.3 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Audeo Oncology would command a market value of $163 million. Audeo Oncology, which was founded in 2006, booked $0 million in sales over the last 12 months. The San Francisco, CA-based company plans to list on the NASDAQ under the symbol AURX. Leerink Swann and Oppenheimer & Co. are the joint bookrunners on the deal.
Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.
Last week, there were 3 IPO pricings . SolarCity ( SCTY ), which leases and installs solar energy systems for homes and businesses, was the week's winner, ending up 47% from its IPO price.